News - afatinib, Oncology

Filter

Current filters:

afatinibOncology

Popular Filters

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

28-10-2013

Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer…

afatinibBoehringer IngelheimGilotrifGiotrifOncologyPharmaceuticalResearch

Boehringer’s cancer drug Giotrif gains European marketing authorization

Boehringer’s cancer drug Giotrif gains European marketing authorization

27-09-2013

Boehringer Ingelheim has been granted marketing authorization from the European Commission for Giotrif…

afatinibBoehringer IngelheimEuropeOncologyPharmaceutical

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

US FDA approves Boehringer Ingelheim's first cancer drug

15-07-2013

In what the family-owned German drug major Boehringer Ingelheim hopes is just the first drug to come…

afatinibBiotechnologyBoehringer IngelheimGilotrifNorth AmericaOncologyPharmaceuticalQiagenRegulation

Boehringer Ingelheim's afatinib NDA gets priority review in USA

16-01-2013

The US subsidiary of German independent drug major Boehringer Ingelheim revealed yesterday that the New…

afatinibBoehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationTomtovok

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment

01-11-2012

At its 3rd International Research & Development press conference, family-owned German drug major Boehringer…

afatinibBoehringer IngelheimnintedanibolodaterolOncologyPharmaceuticalProductionResearchRespimatRespiratory and Pulmonary

Analysts view Boehringer Ingelheim's first move into cancer drug market

11-10-2012

German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing…

afatinibBoehringer IngelheimMarkets & MarketingnintedanibOncologyPharmaceuticalResearchvolasertib

Boehringer Ingelheim files first oncology compound, afatinib, for EU approval

21-09-2012

German family-owned drug major Boehringer Ingelheim said yesterday that it has submitted a Marketing…

afatinibBoehringer IngelheimEuropeOncologyPharmaceuticalRegulation

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Back to top